Introduction
Formulating active pharmaceutical ingredients( APIs) with unfavorable physicochemical properties in drug delivery systems is important to achievet he desired absorption, distribution and duration of the therapeutic effect. [1] Pharmaceutical carriers can also improve tissue selectivity and can thus decrease side effects. The search for formulationsi st herefore an active area of research, and new solutions for drug delivery challenges are being sought. This includes the development of drug delivery vehicles based on liposomes, polymeric micelles, [2] lipid nanoparticles, [3] or biomacromolecules, such as proteins or nucleic acids. [4] [5] [6] [7] [8] One class of pharmaceutically active compounds for which new carrier systems are being developed is the class of anthracyclines.A nthracyclines are chemotherapeutic agentsf rom Streptomyces bacteria that are used extensively as anticancer therapeutics in the clinic. [9] Among the cancers that are being treated with anthracyclines are bladder,b reast, lung ando varian cancers, leukemias and lymphomas. [10] Their mode of action continues to be studied, both experimentally and with computationalm ethods. [11] The better known anthracyclines include daunorubicin, doxorubicin, its epimer epirubicin and idarubicin. Al iposomal nanocarrier for doxorubicin wasa pproved by the FDA in 1995 and was marketed for the treatmento fK aposi's sarcoma or ovarian canceru nder the drug name Doxil. The drug Lipodox is marketed as ac lose derivative of Doxil. [12] Experimental drug delivery systemsf or doxorubicin include formaldehyde conjugates, [13] protein cages, [14] metal organic frameworks, [15] HPMA copolymers [16] and DNA-PEG conjugates. [17] A recent DNA nanocarrier for doxorubicin was shown to have tunable releasep roperties. [18] Nanoscale DNA constructs have also been used for formulating daunorubicin to circumvent drug resistance. [19] Someo ft heser esults suggested that DNAbased structures are suitable as carriers for anthracyclines.
Unfortunately,l ong oligonucleotides or nucleic acids can be difficult and expensive to produce, requiring either solid-phase syntheses or complex biotechnological processes. [20] Further, long linear DNA does not readily form cavities of asize suitable for encapsulatings mall molecules with high efficiency.N or do the complex multistrand assemblies typically produced with the DNA origami technique [21, 22] lend themselves to scale-up for producing the quantities requiredf or clinical studies. Instead, an ew class of oligonucleotide-based compounds that was developed in the realm of DNA nanotechnology seemed more promising. This is the class of branched oligonucleotide hybrids, [23] whose ability to form three-dimensional networks with smallc avities via hybridization,c ombined with the tunability of the interaction strength throughc hangesi nt he sequencea nd length of the DNA chains, andt he biodegradable nature of their DNA arms makes them unique among the novel bio-based materials.
Formulating pharmaceutically active ingredients for drug delivery is ac hallenge. There is an eed for new drug delivery systems that take up therapeutic molecules and release them into biological systems. We propose an ovel mode of encapsulation that involves matrices formed through co-assemblyo fd rugs with adamantane hybrids that feature four CG dimers as sticky ends. Such adamantanes are accessible via inexpensive solution-phase syntheses, and the resulting materials show attractive properties for controlled release. Thisi sd emonstratedf or two different hybridsa nd as eries of drugs, including anticancer drugs, antibiotics, and cyclosporin. Up to 20 molar equivalents of active pharmaceutical ingredients (APIs) are encapsulated in hybrid materials. Encapsulation is demonstrated for DNA-binding and several non-DNAb inding compounds. Nanoparticles wered etected that range in size from 114-835 nm averaged iameter,a nd z potentials were found to be between À29 and + 28 mV.R elease of doxorubicin into serum at nearconstant rates for 10 days was shown, demonstrating the potential for slow release. Thee ncapsulation and releasei ns elfassembling matrices of dinucleotide-bearing adamantanesa ppears to be broadlya pplicable and may thus lead to new drug deliverys ystems for APIs.
We hadr ecently reportedb ranched oligonucleotide hybrids, consistingo fv ery short DNA arms and an organic branching elementa sc ore. [23] Because of multivalent interactions, dinucleotide arms of the sequence 5'-CG-3' suffice to induce the formation of materials upon hybridization of hybrids with four, six or eight arms in aqueous buffer containing magnesium ions. [24, 25] Efficient and scalables olution-phase syntheses make these compounds available at af raction of the cost of linear oligonucleotides. [26, 27] Uptake of DNA staininga gentsd emonstrated that the three-dimensional networks can accommodate guest molecules in the solids formed upon hybridization, [24, 27] but it was unclear whether drugs would be incorporated. This promptedu st ot est whether hybrids with CG zippera rms can act as matrix for the formulation of APIs.
Herein we report that branched oligonucleotide hybrids with CG zippera rms take up significant quantitieso fA PIs, forming inclusion compoundsf rom aqueous solutions ( Figure 1 ). This was first shown fora nthracyclines, and was then extended to otherp harmacologically active agents, including Gleevec.E xploratory work shows that from the inclusion compounds, the API can be released into biological fluids at body temperature. The formulation of doxorubicin contains up to 12 molare quivalents of the drug over the adamantane and has attractive release properties, with near-constant rates of drug release into serum over ten days in an in vitro model system. Figure 2s hows the structure of the branched oligonucleotides that were used to formulate the anthracyclines. Twod ifferent adamantane cores were used. The first is the tetrakis(p-hydroxybiphenyl)adamantane (TBA) core, [27] with stiff spacers between the adamantane branching element and the DNA arms. The second core dubbed "TOA" features just the four hydroxy groups of adamantane tetraol as the attachment pointsf or the DNA arms and was designed to form more hydrophilic lattices with smaller cavities. [28] We expect the short DNA arms to be fully biodegradable by nucleases in the body,w ithout producing toxic metabolites. Substituted adamantanes are knowna s lead structures in medicinal chemistry, [29] and even aminoadamantanes, such as amantadine, [30] rimantadine [31] or adapromine, [32] have been approved as drugs, with acceptable toxicity profiles. The same is true for kemantane, ah ydroxyketone derivativeo fa damantane that is metabolized to ad iol. [32] Adamantane tetraol, the final product of nuclease digestion, is an aliphatic alcohol for which, to the best of our knowledge,n o special toxicity has been reported.
Results and Discussion
As mentioned above, we wished to study whether APIs can be encapsulatedw ith DNA-bearing adamantanes that assemble via base pairing, prompting us to include ab road rangeo f different structures. Figure 3g ives an overview of the APIs studied.
The first series of formulations werep repared with (CG) 4 TBA (1). For this, as olutiono ft he hybrid in 10 mm acetate buffer was heatedt o8 08C, allowed to cool, and treated with as olution of the active pharmaceutical ingredient while at 60 8C, followed by cooling the resulting mixture to 20 8Ci n1 2h. Figure 4s hows representative photographs of solids formed with anthracyclines. Thes olids were isolatedb yc entrifugation and washed once with water.T he amount of remaining API and hybrid carrier were determined in the mother liquorv ia absorption spectroscopy,a nd as ample of the solid was dissolved and also analyzed. Further,c ontrol experiments were performed in every case, in which the API solution was treated with water,r ather than the hybrid solution. Only in three cases (doxorubicin, epirubicin and tetracycline) were small quantities of ap recipitate ( 20 %) found in the control assay upon cooling for up to 3d.T able 1g ives an overview of the resultso f the assays producing the inclusion compounds.
Either of the three anthracycline APIs tested (daunomycin, doxorubicin and epirubicin) gave as olid, with quantitative precipitation of 1 from the buffer.U pt ot welve equivalents of the antibiotics were found in the formulation, whichf or doxorubicin equals 66 %o ft he dry weighto ft he preparation (not considering counterions and hydration). This encouraged us to test other compound classes. First, we formulated other compounds knownt oi nteractw ith DNA, including proflavinea nd mitoxantrone, two intercalators, and netropsin, am inor groove binder.E ither of the drugs was encapsulated well, with ! 5 molar equivalents of the API over the carrier included in the solid (Table1).
The ability of hybrid 1 to form inclusionc ompounds is not limited to drugs known to act on nucleic acids. Imatinib, better known under its trade name Gleevec, ak inase inhibitor and important anticancer medication, was also formulated when combined with 1 in hot aqueous solution,w ith eight equivalents encapsulatedi nt he inclusion compound, which was often initially oily or glassy for this API. Also, an umber of antibiotics was converted into solid inclusion complexes when treated with 1 in the presence of 10 mm magnesium chloride. This included tetracycline, ap rotein biosynthesis inhibitor binding to bacterial ribosomes, of whichf ive equivalents were found in the compound formed with 1,a nd streptomycin, an aminoglycoside and one of the WHOs "essential medicines" ( Table 1 ). The latter does not intercalate and does not feature a chromophore, so that it was hard to quantify by absorbance measurements. So, uptake of the API in the solid was confirmed by TLC. In the preparation, the precipitation of 1 was again near-quantitative according to UV-absorbance.
An antibiotic of vastly different structure and mode of action, gramicidin A, was also incorporatedi nasolid formed with 1 at 10 mm MgCl 2 .H ere, ethanol had to be used in the preparation to ensure sufficient initial solubility of the linear pentadecapeptide,k nownt oa ct as pore-forming membrane channel in bacteria. It is not surprising that just half an equivalent of gramicidinw as incorporated, given its molecular weighto fa lmost 2kDa. We were surprised and encouraged to see that even cyclosporin, an immunosuppressant that is also on the WHO's list of the most effective and safe medicines in the health system that acts on protein targets, formed an equimolar inclusion complex with 1 when formulated with the aid of 25 %e thanol. Further,m ethotrexate, an antifolate anticancer agent and immunosuppressantformed aroughly equimolar in- On the other hand, actinomycin D, also knowna sD actinomycin, at ranscriptional inhibitor that binds to the transcription initiation complex, did not form an solid when combined with 1 in aqueous buffer,e ven when up to 100 mm MgCl 2 was added. Because such ah ighc oncentration of magnesium ions usually induces the precipitation of the hybrid, [23, 24] this suggests that the known DNA-binder can suppress the formation of the insoluble three-dimensional network of the hybrid.N ot surprisingly,c ytochromec,ahemeprotein involved in respiratory chain redox reactions in mitochondriao fo ver 100 amino acid residues does not form an inclusion material with (CG) 4 TBA (1), buti ta lso does not inhibitm aterialf ormation at high magnesium concentration. Here, the large and well-soluble potential guest molecule remains in solution when the hybrid forms an insoluble 3D network (last entry of Table 1) .
We then tested the smaller adamantane tetraol-based hybrid 2 for its ability to form inclusionc ompoundsw ith dox- orubicin and imatinib. For either of the APIs, the temperature at which the hybrid and active ingredient were mixed was varied. Further,i ncreasing molar equivalents of the API were used to test the saturation capacity of the carrier. Figure 5a nd Ta ble 2s how resultsf rom theseexperiments. As with 1,t he uptake of the anthracycline reached saturation at~13 equivalents over hybrid 2.B ecause of the smaller mass of 2 (2.7 kDa) this meansm ore than 70 %p ercent of the dry weight of the preparation was API, ignoringc ounterions and solvation water.W hen 14 equivalents of the anthracycline were used, little of the API stayed unformulated in solution, and the precipitation of the hybrid was also near-quantitative ( Table 2 ). The inclusion efficiency dropped modestly,t o1 0 equivalents, when the mixing was performed at room temperature, rather than 70 8C.
We then monitored the onset of complex formation between drug and carrierb yt emperature-dependent UV/Vis spectrophotometry.W avelength scans at differentt emperatures confirmed that interactions between the aromatic chromophores of API and carrier can be detected by absorption spectroscopy in this case, as indicated by shifts in bands ( Figures S15 -S17, Supporting Information). Figure 6s 8 were cooled, no sigmoidal transition was observed (Figure 6a ). The control experiment using linear DNA octamer (dT) 8 confirmed that the branched oligonucleotide hybrid has properties that are different from those of linear DNA with the same number of nucleotides. However,w hen solutions of doxorubicin and 2 were cooled, an ew transition occurred that manifested itself in af latr egion in the cold and as hift of the "UV-melting curve" to higher temperatures (Figure 6b ). As expected for multimolecular complex formation, this shift in was strongly concentration dependent.W hile at 4 mm concentration of 2, the onset of complex formation was at approx. 20 8C, the flattening of the curve set in at approx.4 08Ca t8mm concentration of 2 under our experimental conditions. This monitoring technique may help to optimize formulations.
For imatinib, the effect of temperature on encapsulation was even stronger than for doxorubicin, so that only at hird of the exceptionally high inclusion efficiency found at 70 8Cr emained when API and carrier were mixed at 22 8C. The ratio of drug and carrier also changed to al ess favorable ratio when the mixingw as performed without heating. Increasing the amount of the drug at 37 8Cl ed to near-quantitative precipitation of the hybrid, but the inclusion efficiency did not go up (Table 2) . So, for this non-intercalating compound, as olubility equilibrium appears to exist that is reminiscent of those found for salts with their characteristicsolubility product.
Inappropriate size and chargeo nc arrier systems can lead to toxic side effects and rapid clearance from the circulation. [3] Therefore, we measured the size and z potentialo fp articles formed when hybrid 2 as carriera nd four representative APIs were mixed at 70 8C, followed by cooling. For this we chose doxorubicin, imatinib, mitoxantrone, and netropsin. Netropsin is an API that did not show signs of interactions with the monomeric form of the carrier,a si ndicated by UV-spectra acquired at different temperatures (Figures S18 and S19, SI). Imatinibi s an API for which ap articularly high encapsulation efficiency had been measured (Table 2 ). Among all drugs tested,m itoxantrone is the API that gave precipitates most readily upon mixingw ith the carrier,s ot hat ac ertain breadth of drug structures was represented in these experiments.T able 3l istst he Figure 6 . Studying complex formation between API and carrier by temperature-dependent UV absorptionat2 60 nm in 50 mm ammonium acetate buffer,p H6.5, at acooling rate of 1 8Cmin À1 .a )Control curves of solutions of (CG) 4 TOA (2,4mm), doxorubicin (16 mm)and amixture of linearD NA octamer (dT) 8 (4 mm)and doxorubicin(16 mm). b) Absorbance curves for solutions of (CG) 4 TOA (4 mm or 8 mm)a nd doxorubicin (16 mm). Hyperchromicities are based on the absorbance at 5 8C. size, as determined by dynamic light scattering (DLS), and the z potentialf or the different APIs. Plots and more detailed data can be found in the SupportingI nformation. Exploratory measurements by transmissione lectron microscopy also showed particles or small aggregates less than 1 mmi nd iameter ( Figure S28, SI) . We then studied the release of APIs from the inclusionc ompounds.F or this, the formulations obtained with the adamantane hybrid were layered with av olume of bovine serum at 37 8C, and the releaseo fthed rug withouta gitation of stirring was measured in the supernatant by UV/Vis spectrophotometry.W here the absorption of the serum was too strong to detect the API in the solution reliably,w ater was used instead. Figure 7s hows the releaseo fd oxorubicin, as measured for the formulation with 2 prepared at different mixing temperatures. As expected, the inclusion compound obtaineda tt he lower mixing temperature released the drug mostr eadily,w hereas the highert emperature forms held on to the API more strongly.I ne ither case, the amount released leveled off over the courseo fone day.T he extent to which release occurred within 24 hf or an umber of different APIs and preparations was measured for the respective inclusion compounds,a nd the results are listed in Table 4 .
The slowest release was measured for the anthracylines, prompting us to perform al ong-term assay (Figure 8 ). For this, the supernatant was aspirated at the endo fa24 hp eriod,a nd replaced with fresh serum, followedb yr enewed incubation at 37 8Cw ithouta gitation or mixing. At the end of each period, the API content in the serum was measured and the process repeated. After ten days, the daunomycin inclusion compound was all but fully dissolved, leadingt oasharp drop in what had been af airly steady rate of release. For doxorubicin, the amount released per day was smaller,s ot hat after 11 days, ap- Releaseo fd aunomycin (red squares) or doxorubicin (blue rhombuses), into fetal bovine serum (FBS, 100 mL) from formulations with 1,after 1dat 37 8Cwithout shaking.T he concentrationsofd aunomycin and doxorubicinwere determined by UV/Vis absorption. After each 24 hperiod, the sample was centrifuged and the serum was replaced with an ew aliquot of FBS, followed by incubation at 37 8Cf or another 24 h. After 10 d,~90 %o f the daunomycin and 50 %oft he doxorubicin were released from the solids. proximately half of the formulation remained. At that time point, still more than at hird of the quantity released during the first day was found in the supernatant after 24 h. That the hybrid matrix dissolved during the releasep rocessw as confirmed by analyzing the supernatant in control assays with water,w hich allowed direct quantification of either component of the inclusionc ompound. Exploratory experiments with hybrids featuring longerD NA arms suggest that even larger quantities of anthracyclines can be encapsulated, and that even slower releasef rom the hybridized networks can be achieved.
Conclusions
In conclusion, we showt hat adamantanes with four CG dimer appendages have the ability to form inclusionc omplexes with ab road range of different APIs, providing potential new formulations for an umber of drugs that are on the WHO's list of Essential Medicines. While initially focused on DNA-binding drugs, our study showedt hat new inclusion compounds can also be formed with other APIs. For anthracyclines,the amount that is encapsulated far exceeds the two equivalentst hat would be expected for intercalation. Instead, ac ombination of intercalation and encapsulationi nc avities formed by the hybrid lattice upon hybridization of the CG dimer arms is the most likelym olecular scenario. In recenty ears, an ever increasing number of biologics has been approved as active ingredients of pharmaceuticalp reparations.Here we show that ap runed-down version of ab iological (an oligonucleotide) in combinationw ith an adamantane core can be used to generate slow release formulations.A sa biopolymer,D NA is biodegradable. For TOA hybrids, the remaining adamantane tetraoli sa na liphatic alcohol that is unlikely to pose at oxicological problem.F urther,t he cost of our carriers is much lower than that of therapeutic oligonucleotides, because efficient solution-phases yntheses exists that are scalablea nd that use inexpensive, commercial startingm aterials. [28] With al oadingc apacity of up to 70 %o ft he dry weight, the hybridsh avet he potential to become alternatives to establishedc arriers for active pharmaceutical ingredients. Among the tasks that lay ahead are expanding the current work focused on molecular recognitiona nd nanostructuring to biological studies. We are also workingo na pproaches to expand this study into the realm of smart chemistry-based delivery, [33] as well as other forms of next generation nanomedicines, including those suitable for encapsulatingb iologics.
Experimental Section
General.T he active pharmaceutical ingredients (APIs), fetal bovine serum (FBS) and water (Chromasolv for HPLC) were from Sigma Aldrich (Deisenhofen, Germany) or TCI Europe (Zwijndrecht, Belgium) and were used without further purification. The hybrids (CG) 4 TBA (1)a nd (CG) 4 TOA( 2)w ere synthesized as described. [27, 28] Thin layer chromatography (TLC) was performed with precoated silica gel sheets (SIL G/UV254 from Machery-Nagel) with visualization by ultraviolet light (254 nm) or staining. UV/Vis spectra were recorded using aN D-1000 spectrophotometer (NanoDrop;p eQlab, Erlangen, Germany). For baseline correction, water or FBS was used as reference. MALDI-TOFm ass spectra were acquired on aB ruker REFLEX IV spectrometer.T he spectra were measured in linear negative mode using am atrix/comatrix mixture of 2,4,6-trihydroxyacetophenone (0.3 m in EtOH) and diammonium citrate (0.1 m in H 2 O) at a ratio of 2:1( v/v). Absorption spectroscopy was performed on a Lambda 25 spectrophotometer (PerkinElmer). Dynamic light scattering (DLS) data and z potential were measured with aZ etasizer Nano ZS90 system with 908 detector position. Transmission electron microscopy (TEM) was performed on an FEI Te cnai G2 electron microscope at an acceleration voltage of 200 kV.
Inclusion compounds of APIs with hybrids.T he following protocol is representative and was used for all anthracyclines tested (daunomycin, doxorubicin and epirubicin), as well as proflavine, mitoxantone, netropsin and imatinib. As olution of (CG) 4 TBA (1, 50 mL, 1mm,5 0nmol) in NH 4 OAc buffer (10 mm)w as diluted with H 2 O( 50 mL) and heated to 70 8Cf or 15 min. As olution of doxorubicin (750 nmol, 15 equiv) in H 2 O( 100 mL) at 70 8Cw as added in one portion and the mixture was allowed to cool down to room temperature in aw ater bath during 12 h. The red solid formed was separated by centrifugation (16 300 g, 2min), the supernatant was aspirated and the solid was washed with water (100 mL). The supernatant was analyzed by UV/Vis measurement at 260 nm to determine the content of hybrid and, at the maximum of doxorubicin spectrum (487 nm), to determine the content of the API. Hybrid 1 was precipitated quantitatively (> 95 %);t he ratio of doxorubicin/ hybrid determined was 12:1. Further,asmall sample of the solid (0.1 mg) was dissolved in H 2 O/EtOH (300 mL, 2:1, v/v at 60 8C) and analyzed by MALDI-TOF MS. In the control assay lacking the hybrid, as olution of doxorubicin (200 mL, 150 mm;i nN H 4 OAc buffer 10 mm)w as heated to 70 8Ca nd cooled to room temperature over 12 h. The sample was centrifuged and analyzed by absorption measurement, as described above. When the same assay was repeated five times, the numerical value of the encapsulation efficiency was found to vary by less than 10 %b etween the experiments.
Inclusion compounds of APIs with (CG) 4 TBA with addition of MgCl 2 .T he following protocol was used for tetracycline, streptomycin, methotrexate, gramicidin A, cyclosporin A, actinomycin A and cytochrome ca nd is representative for encapsulation with addition of magnesium chloride. As olution of (CG) 4 TBA (1,1 0mL, 1mm,1 0nmol) in NH 4 OAc buffer (10 mm)w as diluted with H 2 O (90 mL) and heated to 70 8Cf or 15 min. Then, as olution of methotrexate (150 nmol, 15 equiv) in H 2 O( 100 mL) at 70 8Cw as added in one portion and the mixture was allowed to cool to room temperature in aw ater bath over 12 h. After addition of MgCl 2 solution (2 mL, 1 m,2mmol, final concentration 10 mm), the mixture was vortexed for 10 sa nd then stored in the dark at room temperature for 24 h. The yellow precipitate was separated by centrifugation (16 300 g, 2min) . The supernatant was aspirated and analyzed by UV/Vis measurement at 260 nm to determine the content of hybrid, and, at the maximum of the methotrexate spectrum (373 nm), to determine the concentration of the API. The hybrid was found to have precipitated to 90 %o ft he initial amount, and the stoichiometric ratio of methotrexate/hybrid determined was 1:1. Ac ontrol sample without the hybrid yielded no solid.
Release of anthracyclines into serum.T he following protocol is representative and was used for all (CG) 4 TBA inclusion compounds loaded with anthracyclines (daunomycin, doxorubicin, or epirubicin). As ample of the solid loaded with the anthracycline was prepared as described above. After centrifugation and washing with water,t he solid was treated with fetal bovine serum (FBS, 100 mL) without mixing or shaking, and was left standing at 37 8Ci natemperature-controlled incubator oven. Samples of the supernatant (1 mL) were drawn at stated intervals and analyzed by UV-VIS absorption measurement. Absorption at the maxima of the anthracycline spectrum was used to determine the content of the anthracycline in the supernatant. After sampling, the remaining solid was separated by centrifugation (16 300 gf or 1min), and fresh FBS (100 mL) was added, as described above, followed by incubation for another 24 ha t3 7 8C. This procedure was repeated daily for 12 d. The data points reported in Figures 7, Figure 8 , and Ta ble 4 are averages of three or four individual measurements that typically differed by less than 5%.
Monitoring by absorption spectroscopy.T he following protocol is representative. It was used for monitoring the interactions of (CG) 4 TOA( 2)a nd doxorubicin. As olution of (CG) 4 TOA (2,4 .9 mL, 0.83 mm,4nmol) in NH 4 OAc buffer (10 mm,p H6.5) was diluted with HPLC grade water to af inal volume of 1mL, followed by heating at 70 8Ci nasemimicro UV cuvette. Then, an aliquot of a stock solution of doxorubicin (1.0 mL, 16 mm,1 6nmol, 16 equiv) was added. The final concentrations in the solution were 4 mm 2 and 16 mm doxorubicin. The cuvette was heated to 70 8Ct os tart measuring the temperature-dependent spectra (wavelength scans, Figures S15-S19, Supporting Information). For the measurements at 260 nm shown in Figure 6 , samples that had cooled to 20 8C were briefly shaken and placed in aultrasonic bath prior to heating again to 70 8Ca nd acquisition of the absorption versus temperature curves.
Size measurement via dynamic light scattering.T he following protocol is representative and was used for the mixture of (CG) 4 TOA( 2)a nd doxorubicin. As tock solution of (CG) 4 TOA( 2)i n NH 4 OAc buffer (10 mm)w as diluted with H 2 O( HPLC grade) to a volume of 100 mLa nd ac oncentration of 10 mm and was then heated to 70 8C. After addition of doxorubicin (final concentration 150 mm), the solution was transferred to ac uvette and placed in the Zetasizer.T he final concentration of the NH 4 OAc buffer was 100 mm.T wo measurement runs were performed, leading to the results shown in Ta ble 3a nd Figures S20-S23 (SI).
Zeta potential of particles.Astock solution of (CG) 4 TOA( 2)i n NH 4 OAc buffer (10 mm)w as diluted with H 2 Ot oav olume of 100 mL, resulting in ac oncentration of 20 mm 2,f ollowed by heating at 70 8C, addition of doxorubicin (15 equiv), cooling to 25 8C, and dilution to af inal volume of 800 mLw ith water.T he final concentrations were 2.5 mm (CG) 4 TOA,3 7.5 mm doxorubicin, and 30 mm NH 4 OAc buffer.T he capillary cell was prepared by rinsing with ethanol (20 mL) and water (10 mL). The sample solution (0.8 mL) was placed in the capillary cell and inserted into the Zetasizer,l eading to the results shown in Ta ble 3a nd in Figures S24-S27 (z potential).
Transmission electron microscopy.Asolution of 2 (100 mm, 100 mL) was heated to 80 8C, cooled to 50 8Ci n2h, and treated with doxorubicin (4 equiv), followed by cooling to 20 8Ci n8h, resulting in ar eddish precipitate. The mixture was vortexed for 10 s and as ample was placed on ac opper grid (coated with carbon, Plano Wetzlar).A fter 5min, excess liquid was removed from the grid using af ilter paper.T hen, uranyl formiate (5 mL, 1% in H 2 O) was added and immediately removed by capillary forces with filter paper.T his procedure was repeated once, with removal of excess uranyl formiate solution after 20 s. The grid was dried and used for electron microscopy.
Supporting Information.R epresentative spectra of starting materials, inclusion compounds and samples from the drug release assay can be found in the Supporting Information.
